NCT05171374 (RATIONALE) is a clinical trial of Dabrafenib in Melanoma Stage III, sponsored by MelanomaPRO, Russia.

Who is sponsoring NCT05171374?

NCT05171374 is sponsored by MelanomaPRO, Russia.

What drugs are being tested in NCT05171374?

Interventions in NCT05171374: Dabrafenib, Trametinib.

What condition does NCT05171374 study?

NCT05171374 studies Melanoma Stage III, Melanoma Stage IV, Melanoma.

Is NCT05171374 still recruiting?

NCT05171374 is currently status unknown. Last updated 1 June 2022.

Last reviewed 2022-06-01 · How we verify

NCT05171374: RATIONALE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE

Status unknown Last updated 1 June 2022

What this trial tests

trial testing Dabrafenib in Melanoma Stage III in 500 participants. Status unknown.

Timeline

30 September 2021

Primary endpoint
30 September 2023

30 September 2024

Quick facts

Lead sponsor	MelanomaPRO, Russia
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	500
Start date	30 September 2021
Primary completion	30 September 2023
Estimated completion	30 September 2024
Sites	15 locations across Russia

Drugs / interventions tested

Dabrafenib (dabrafenib) — full drug profile →
Trametinib (trametinib) — full drug profile →

Conditions studied

Melanoma Stage III — all drugs for Melanoma Stage III →
Melanoma Stage IV — all drugs for Melanoma Stage IV →
Melanoma — all drugs for Melanoma →

Sponsor

MelanomaPRO, Russia

Who can join

18 and older, any sex, with Melanoma Stage III or Melanoma Stage IV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective evaluation of clinical outcomes in patients with resectable or metastatic BRAF+ melanoma treated with dabrafenib and trametinib in real practice

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The future of targeted kinase inhibitors in melanoma.
Caksa S, Baqai U, Aplin AE. · · 2022 · cited 25× · PMID 35513054 · DOI 10.1016/j.pharmthera.2022.108200

Verify or expand the search:

Other trials of Dabrafenib

Trials testing the same drug.

NCT07110246 — Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas · Phase 2 · recruiting
NCT07010393 — Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study · Phase 4 · not yet recruiting
NCT06119789 — Precision Cancer Therapy in Rare Cancers · Phase 2 · recruiting
NCT06739395 — Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion · Phase 2 · recruiting
NCT06475989 — Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer · Phase 3 · recruiting

Other recruiting trials for Melanoma Stage III

Currently open trials in the same condition.

NCT06204991 — To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma · Phase 1 · recruiting
NCT06551064 — Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients · Phase 1 · active not recruiting
NCT06508775 — Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies · NA · recruiting
NCT05655312 — MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma · Phase 1, PHASE2 · recruiting
NCT05652673 — Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial · NA · recruiting

Other MelanomaPRO, Russia trials

Trials by the same sponsor.

NCT03663647 — Advanced Melanoma in Russian Experience · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05171374 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MelanomaPRO, Russia
Last refreshed: 1 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05171374.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing